Fig. 1From: Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignanciesMedian percent change in (a) spleen volume and (b) spleen length from baseline in efficacy evaluable population of the phase 2 studyBack to article page